Encontrados 7 documentos, a visualizar página 1 de 1
Predictors of Secukinumab Treatment Response and Continuation in Axial Spondylo...
Pons, Marion; Georgiadis, Stylianos; Hetland, Merete Lund; Ahmadzay, Zohra Faizy; Rasmussen, Simon; Christiansen, Sara N.; Di Giuseppe, DanielaPublisher Copyright: © 2025 The Journal of Rheumatology.; Objective. In patients with axial spondyloarthritis (axSpA) initiating secukinumab (SEC), we aimed to identify baseline (treatment start) predictors of achieving low disease activity (LDA) after 6 months, as measured by the Axial Spondyloarthritis Disease Activity Score using C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity...
Differences in the response to TNF inhibitors at distinct joint locations in pa...
Ciurea, Adrian; Kissling, Seraphina; Götschi, Andrea; Ørnbjerg, Lykke Midtbøll; Rasmussen, Simon Horskjær; Tamási, Bálint; Möller, BurkhardPublisher Copyright: © The Author(s) 2025.; Background: Efficacy of tumour necrosis factor inhibitors (TNFi) for peripheral arthritis in patients with psoriatic arthritis (PsA) has been established in randomized clinical trials that have used improvement in summated joint counts as an outcome. Whether joints at different anatomical locations might respond differentially to TNFi remains unknown. The aim of the s...
Second and third TNF inhibitors in European patients with axial spondyloarthritis
Linde, Louise; Ørnbjerg, Lykke Midtbøll; Brahe, Cecilie Heegaard; Wallman, Johan Karlsson; Di Giuseppe, Daniela; Závada, Jakub; Castrejon, IsabelOBJECTIVE: To investigate real-world effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA) and the association with 1) treatment line (second and third TNFi-series) and 2) reason for withdrawal from the preceding TNFi (lack of efficacy (LOE) versus adverse events (AE)). METHODS: Prospectively collected routine care data from 12 European registries were pooled....
Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing...
Georgiadis, Stylianos; Ørnbjerg, Lykke Midtbøll; Michelsen, Brigitte; Kvien, Tore K.; Giuseppe, Daniela Di; Wallman, Johan K.; Závada, JakubFunding Information: On behalf of the EuroSpA Scientific Committee, the authors acknowledge Novartis Pharma AG and IQVIA for supporting the EuroSpA Research Collaboration Network. Publisher Copyright: © 2024 The Journal of Rheumatology.; Objective. Ankylosing Spondylitis Disease Activity Score based on C-reactive protein (ASDAS-CRP) is recommended over ASDAS based on erythrocyte sedimentation rate (ASDAS-ESR) t...
Recording of non-musculoskeletal manifestations, comorbidities and safety outco...
Ahmadzay, Zohra F.; Heberg, Jette; Jørgensen, Jacob B.; Ørnbjerg, Lykke M.; Østergaard, Mikkel; Møller-Bisgaard, Signe; Michelsen, BrigitteFunding Information: This work was supported by Novartis Pharma AG. EuroSpA was financially supported by Novartis. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit the manuscript. Publisher Copyright: © 2024 The Author(s).; Objectives: Real-world evidence is needed to inform treatment strategies for patients with PsA and axial SpA (axSpA) who h...
Corrigendum to ‘Predictors of ASDAS-CRP inactive disease in axial spondyloarthr...
Ørnbjerg, Lykke M.; Linde, Louise; Georgiadis, Stylianos; Rasmussen, Simon H.; Lindström, Ulf; Askling, Johan; Michelsen, Brigitte; Giuseppe, Daniela DiThe authors regret that the following incorrect values have been published in the original paper: In the abstract: Line 11-12: “age, per year: 0.97 (0.97-0.98)” should be “age, per year: 0.98 (0.97-0.99)” Line 12: “men vs. women: 1.88 (1.60-2.22)” should be “men vs. women: 1.79 (1.51-2.12)” Line 12: “current vs. non-smoking: 0.76 (0.63-0.91)” should be “current vs. non-smoking: 0.72 (0.59-0.87)” Line 12-13: “HL...
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during trea...
Ørnbjerg, Lykke M.; Linde, Louise; Georgiadis, Stylianos; Rasmussen, Simon H.; Lindström, Ulf; Askling, Johan; Michelsen, Brigitte; Giuseppe, Daniela DiFunding Information: LMØ, LL, SG and SHR: research grants from Novartis; UL: none; DDG none; JKW: consultant of AbbVie, Amgen, Celgene, Eli Lilly and Novartis; BG: research grants from Pfizer, Abbvie and BMS; LP: consultant of Novartis Finland, UCB Pharma, Pfizer, Sanofi, BMS, AbbVie, Amgen, Celgene, Eli Lilly, Boehringer-Ingelheim, Mylan; KL: consulting and/or speaking fees from Amgen, Johnson and Johnson and ...